These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36450964)

  • 1. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes.
    Dri DA; Rinaldi F; Carafa M; Marianecci C
    Drug Deliv Transl Res; 2023 Mar; 13(3):757-769. PubMed ID: 36450964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office.
    Dri DA; Gaucci E; Torrieri I; Carafa M; Marianecci C; Gramaglia D
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surfactants, Nanomedicines and Nanocarriers: A Critical Evaluation on Clinical Trials.
    Dri DA; Marianecci C; Carafa M; Gaucci E; Gramaglia D
    Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33805639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges.
    Musazzi UM; Franzè S; Condorelli F; Minghetti P; Caliceti P
    Adv Healthc Mater; 2023 Dec; 12(30):e2301956. PubMed ID: 37718353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping of the available standards against the regulatory needs for nanomedicines.
    Halamoda-Kenzaoui B; Holzwarth U; Roebben G; Bogni A; Bremer-Hoffmann S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1531. PubMed ID: 29923692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
    Mühlebach S
    Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities.
    Agrahari V; Agrahari V
    Drug Discov Today; 2018 May; 23(5):974-991. PubMed ID: 29406263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicines: The magic bullets reaching their target?
    Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
    Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines.
    Albalawi F; Hussein MZ; Fakurazi S; Masarudin MJ
    Int J Nanomedicine; 2021; 16():161-184. PubMed ID: 33447033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances and challenges in nanocarriers and nanomedicines for veterinary application.
    Carvalho SG; Araujo VHS; Dos Santos AM; Duarte JL; Silvestre ALP; Fonseca-Santos B; Villanova JCO; Gremião MPD; Chorilli M
    Int J Pharm; 2020 Apr; 580():119214. PubMed ID: 32165220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicines: addressing the scientific and regulatory gap.
    Tinkle S; McNeil SE; Mühlebach S; Bawa R; Borchard G; Barenholz YC; Tamarkin L; Desai N
    Ann N Y Acad Sci; 2014 Apr; 1313():35-56. PubMed ID: 24673240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives.
    Souto EB; Blanco-Llamero C; Krambeck K; Kiran NS; Yashaswini C; Postwala H; Severino P; Priefer R; Prajapati BG; Maheshwari R
    Acta Biomater; 2024 May; 180():1-17. PubMed ID: 38604468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory landscape of nanotechnology and nanoplastics from a global perspective.
    Allan J; Belz S; Hoeveler A; Hugas M; Okuda H; Patri A; Rauscher H; Silva P; Slikker W; Sokull-Kluettgen B; Tong W; Anklam E
    Regul Toxicol Pharmacol; 2021 Jun; 122():104885. PubMed ID: 33617940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory aspects on nanomedicines.
    Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
    Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced nitric oxide donors: chemical structure of NO drugs, NO nanomedicines and biomedical applications.
    Yang Y; Huang Z; Li LL
    Nanoscale; 2021 Jan; 13(2):444-459. PubMed ID: 33403376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in the development of nanoparticle-based imaging agents: Characterization and biology.
    Crist RM; Dasa SSK; Liu CH; Clogston JD; Dobrovolskaia MA; Stern ST
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jan; 13(1):e1665. PubMed ID: 32830448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced Health Technologies and Nanotechnologies in Neurodegenerative Diseases.
    Naziris N; Demetzos C
    Adv Exp Med Biol; 2021; 1339():317. PubMed ID: 35023119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicines in the EU-Regulatory Overview.
    Pita R; Ehmann F; Papaluca M
    AAPS J; 2016 Nov; 18(6):1576-1582. PubMed ID: 27527889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.